Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
| Autor: | Elihu H. Estey, Hagop M. Kantarjian, Stephan Faderl, Jianqin Shan, Barry E. Storer, Andrei R. Shustov, Stephen H. Petersdorf, Sherry Pierce, Derek L. Stirewalt, John M. Pagel, Paul C. Hendrie, Elizabeth Harrington, Frederick R. Appelbaum, Pamela S. Becker |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Myeloid business.industry medicine.medical_treatment Salvage therapy Hematology Pharmacology medicine.disease Gastroenterology Granulocyte colony-stimulating factor Leukemia medicine.anatomical_structure Internal medicine Toxicity Cytarabine medicine Clofarabine business medicine.drug |
| Zdroj: | British Journal of Haematology. 155:182-189 |
| ISSN: | 0007-1048 |
| DOI: | 10.1111/j.1365-2141.2011.08831.x |
| Popis: | This phase I/II study was conducted to determine the maximum tolerated dose, toxicity, and efficacy of clofarabine in combination with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming (GCLAC), in the treatment of patients with relapsed or refractory acute myeloid leukaemia (AML). Dose escalation of clofarabine occurred without dose-limiting toxicity, so most patients were treated at the maximum dose, 25 mg/m(2) per day with cytarabine 2 g/m(2) per day, each for 5 d, and G-CSF 5 μg/kg, beginning the day before chemotherapy and continuing daily until neutrophil recovery. The complete remission (CR) rate among the 46 evaluable patients was 46% (95% confidence interval [CI] 31-61%) and the CR + CR but with a platelet count |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text